What is Express Gene?
Based in Miami, Florida, Express Gene operates as a CLIA and CAP accredited molecular diagnostics laboratory. The organization provides a comprehensive suite of DNA and genetic testing services, ranging from familial cancer panels and prenatal screening to diabetes and ancestry diagnostics. By bridging the gap between complex genetic data and actionable health insights, Express Gene empowers healthcare providers and patients alike. Their commitment to accessibility is further evidenced by their bilingual service offerings, ensuring that critical genetic information is communicated effectively to a diverse patient demographic. The company occupies a vital niche in the healthcare ecosystem, leveraging advanced molecular technology to drive precision medicine forward.
How much funding has Express Gene raised?
Express Gene has raised a total of $5M across 1 funding round:
Debt
$5M
Debt (2026): $5M with participation from Newtek Bank, National Association
Key Investors in Express Gene
Newtek Bank, National Association
A national bank providing comprehensive financial solutions and business lending services to support the growth of small and mid-sized enterprises.
What's next for Express Gene?
With the recent influx of capital, Express Gene is well-positioned to scale its enterprise-level operations and broaden its diagnostic footprint. The strategic deployment of these funds will likely focus on optimizing laboratory throughput, integrating advanced bioinformatics, and potentially expanding its geographic reach. As the demand for personalized medicine and genetic screening continues to accelerate, the company is poised to leverage its accreditation and technical expertise to capture additional market share. Future growth will likely hinge on the firm's ability to maintain high-quality diagnostic standards while navigating the evolving regulatory landscape of the molecular testing industry.
See full Express Gene company page
